Galectin Therapeutics Inc.GALTNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank73
3Y CAGR-9.6%
5Y CAGR+5.5%
Year-over-Year Change
Research and development spending
3Y CAGR
-9.6%/yr
vs +48.8%/yr prior
5Y CAGR
+5.5%/yr
Recent deceleration
Acceleration
-58.4pp
Decelerating
Percentile
P73
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $23.47M | -35.8% |
| 2024 | $36.57M | +13.8% |
| 2023 | $32.13M | +1.2% |
| 2022 | $31.74M | +33.2% |
| 2021 | $23.82M | +32.5% |
| 2020 | $17.98M | +140.7% |
| 2019 | $7.47M | +15.4% |
| 2018 | $6.47M | -44.8% |
| 2017 | $11.72M | -23.5% |
| 2016 | $15.32M | - |